NIAGEN BIOSCIENCE INC (NAGE) Stock Fundamental Analysis
NASDAQ:NAGE - Nasdaq - US1710774076 - Common Stock - Currency: USD
Taking everything into account, NAGE scores 6 out of 10 in our fundamental rating. NAGE was compared to 55 industry peers in the Life Sciences Tools & Services industry. NAGE has an excellent financial health rating, but there are some minor concerns on its profitability. NAGE shows excellent growth, but is valued quite expensive already. These ratings would make NAGE suitable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year NAGE was profitable.
In the past year NAGE had a positive cash flow from operations.
In the past 5 years NAGE reported 4 times negative net income.
In multiple years NAGE reported negative operating cash flow during the last 5 years.
1.2 Ratios
NAGE has a Return On Assets of 17.34%. This is amongst the best in the industry. NAGE outperforms 94.55% of its industry peers.
NAGE has a Return On Equity of 25.49%. This is amongst the best in the industry. NAGE outperforms 94.55% of its industry peers.
With an excellent Return On Invested Capital value of 17.27%, NAGE belongs to the best of the industry, outperforming 92.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.34% | ||
| ROE | 25.49% | ||
| ROIC | 17.27% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 13.07%, NAGE belongs to the top of the industry, outperforming 87.27% of the companies in the same industry.
NAGE has a better Operating Margin (12.26%) than 70.91% of its industry peers.
NAGE's Gross Margin of 62.51% is amongst the best of the industry. NAGE outperforms 83.64% of its industry peers.
NAGE's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.26% | ||
| PM (TTM) | 13.07% | ||
| GM | 62.51% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), NAGE is creating some value.
Compared to 1 year ago, NAGE has more shares outstanding
Compared to 5 years ago, NAGE has more shares outstanding
The debt/assets ratio for NAGE has been reduced compared to a year ago.
2.2 Solvency
NAGE has an Altman-Z score of 24.22. This indicates that NAGE is financially healthy and has little risk of bankruptcy at the moment.
NAGE has a better Altman-Z score (24.22) than 100.00% of its industry peers.
There is no outstanding debt for NAGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 24.22 |
ROIC/WACC1.63
WACC10.59%
2.3 Liquidity
NAGE has a Current Ratio of 3.66. This indicates that NAGE is financially healthy and has no problem in meeting its short term obligations.
NAGE has a Current ratio (3.66) which is comparable to the rest of the industry.
A Quick Ratio of 3.12 indicates that NAGE has no problem at all paying its short term obligations.
NAGE's Quick ratio of 3.12 is fine compared to the rest of the industry. NAGE outperforms 61.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.66 | ||
| Quick Ratio | 3.12 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 440.00% over the past year.
NAGE shows a strong growth in Revenue. In the last year, the Revenue has grown by 29.77%.
NAGE shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.56% yearly.
EPS 1Y (TTM)440%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%700%
Revenue 1Y (TTM)29.77%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.59%
3.2 Future
NAGE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 54.99% yearly.
The Revenue is expected to grow by 22.20% on average over the next years. This is a very strong growth
EPS Next Y25.8%
EPS Next 2Y47.51%
EPS Next 3Y54.99%
EPS Next 5YN/A
Revenue Next Year26.78%
Revenue Next 2Y23.81%
Revenue Next 3Y22.2%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 82.76, the valuation of NAGE can be described as expensive.
The rest of the industry has a similar Price/Earnings ratio as NAGE.
Compared to an average S&P500 Price/Earnings ratio of 26.59, NAGE is valued quite expensively.
Based on the Price/Forward Earnings ratio of 64.66, the valuation of NAGE can be described as expensive.
NAGE's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of NAGE to the average of the S&P500 Index (22.39), we can say NAGE is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 82.76 | ||
| Fwd PE | 64.66 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NAGE is on the same level as its industry peers.
NAGE's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 56.71 | ||
| EV/EBITDA | 72 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates NAGE does not grow enough to justify the current Price/Earnings ratio.
NAGE has a very decent profitability rating, which may justify a higher PE ratio.
NAGE's earnings are expected to grow with 54.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.21
PEG (5Y)N/A
EPS Next 2Y47.51%
EPS Next 3Y54.99%
5. Dividend
5.1 Amount
NAGE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
14.07
+0.55 (+4.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners30.29%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner Change6.42%
Market Cap1.11B
Analysts85
Price Target12.68 (-9.88%)
Short Float %4.26%
Short Ratio2.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)297.02%
Min EPS beat(2)252.87%
Max EPS beat(2)341.18%
EPS beat(4)4
Avg EPS beat(4)295.72%
Min EPS beat(4)100%
Max EPS beat(4)488.82%
EPS beat(8)8
Avg EPS beat(8)176.93%
EPS beat(12)11
Avg EPS beat(12)125.5%
EPS beat(16)13
Avg EPS beat(16)92.26%
Revenue beat(2)2
Avg Revenue beat(2)8.54%
Min Revenue beat(2)6.81%
Max Revenue beat(2)10.27%
Revenue beat(4)3
Avg Revenue beat(4)4.57%
Min Revenue beat(4)-4.88%
Max Revenue beat(4)10.27%
Revenue beat(8)4
Avg Revenue beat(8)0.77%
Revenue beat(12)5
Avg Revenue beat(12)-0.38%
Revenue beat(16)6
Avg Revenue beat(16)-0.79%
PT rev (1m)37.77%
PT rev (3m)N/A
EPS NQ rev (1m)-28.55%
EPS NQ rev (3m)N/A
EPS NY rev (1m)5.71%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0.49%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.6%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 82.76 | ||
| Fwd PE | 64.66 | ||
| P/S | 10.27 | ||
| P/FCF | 56.71 | ||
| P/OCF | 56.27 | ||
| P/B | 20.03 | ||
| P/tB | 20.14 | ||
| EV/EBITDA | 72 |
EPS(TTM)0.17
EY1.21%
EPS(NY)0.22
Fwd EY1.55%
FCF(TTM)0.25
FCFY1.76%
OCF(TTM)0.25
OCFY1.78%
SpS1.37
BVpS0.7
TBVpS0.7
PEG (NY)3.21
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.34% | ||
| ROE | 25.49% | ||
| ROCE | 21.87% | ||
| ROIC | 17.27% | ||
| ROICexc | 207.52% | ||
| ROICexgc | 221.7% | ||
| OM | 12.26% | ||
| PM (TTM) | 13.07% | ||
| GM | 62.51% | ||
| FCFM | 18.11% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
F-Score7
Asset Turnover1.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 19.42% | ||
| Cap/Sales | 0.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 140.47% | ||
| Profit Quality | 138.55% | ||
| Current Ratio | 3.66 | ||
| Quick Ratio | 3.12 | ||
| Altman-Z | 24.22 |
F-Score7
WACC10.59%
ROIC/WACC1.63
Cap/Depr(3y)21.85%
Cap/Depr(5y)22.95%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)440%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%700%
EPS Next Y25.8%
EPS Next 2Y47.51%
EPS Next 3Y54.99%
EPS Next 5YN/A
Revenue 1Y (TTM)29.77%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.59%
Revenue Next Year26.78%
Revenue Next 2Y23.81%
Revenue Next 3Y22.2%
Revenue Next 5YN/A
EBIT growth 1Y402.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year592.78%
EBIT Next 3Y156.77%
EBIT Next 5YN/A
FCF growth 1Y455.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y485.46%
OCF growth 3YN/A
OCF growth 5YN/A